Prescriber Resources
Enrolling in POMALYST REMS®
In order to prescribe POMALYST® (pomalidomide), you must enroll in the POMALYST REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to the Celgene Customer Care at 1-888-432-9325.
Prescribing POMALYST for your patients
In order to receive POMALYST, your patients must also be enrolled in the POMALYST REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.
Learning more about POMALYST REMS®
For additional information about the POMALYST REMS® program, please see the educational materials below.
Please report adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST to Celgene using any of the following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST may also be reported to the FDA MedWatch Reporting System using any of the following methods: |
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
